Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AlconXSWX:ALC +1.63%74 Days Sales Outstanding is 66.80 as of Mar. 2026, which is 7% below its 10-year median of 72.04. GuruFocus rates XSWX:ALC with a GF Score™ of 74/100 and a GF Value™ of CHF74.50 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 812 Medical Devices & Instruments companies, Alcon ranks worse than 53.33% on this metric.
Alcon's average Accounts Receivable for the
three
months ended in Mar. 2026 was CHF1,560 Mil. Alcon's Revenue for the
three
months ended in Mar. 2026 was CHF2,130 Mil.
Hence, Alcon's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 66.80.
The historical rank and industry rank for Alcon's Days Sales Outstanding or its related term are showing as below:
XSWX:ALC'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 66.23 Med: 72.04 Max: 83.87
Current: 67.87
During the past 10 years, Alcon's highest Days Sales Outstanding was 83.87. The lowest was 66.23. And the median was 72.04.
XSWX:ALC's Days Sales Outstanding is ranked worse than 53.33% of 812
companies
in the Medical Devices & Instruments industry
Industry Median: 65.165
vs XSWX:ALC: 67.87
Alcon's Days Sales Outstanding
declined
from Mar. 2025 (67.45) to Mar. 2026 (66.80).
Alcon (XSWX:ALC) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Alcon Days Sales Outstanding Related Terms
Alcon Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Alcon's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ALC vs ISRG, BDX, MDLN: Days Sales Outstanding Comparison
For the Medical Instruments & Supplies subindustry, Alcon's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alcon Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Alcon's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Alcon's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alcon (XSWX:ALC) has a Days Sales Outstanding of 66.80 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Alcon and its competitors. This is near median its historical median of 72.04. Over the past decade, Alcon's Days Sales Outstanding has ranged from 66.23 to 83.87. According to the industry distribution chart, Alcon ranks #433 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 53.3%.
Is Alcon's Days Sales Outstanding too high?
Alcon's current Days Sales Outstanding of 66.80 is near median its 10-year median of 72.04. Over the past 10 years, this metric has ranged from a low of 66.23 to a high of 83.87. The Medical Devices & Instruments industry median Days Sales Outstanding is 65.17. Alcon's value of 66.80 is 2.5% above this industry median. Based on the distribution chart, Alcon ranks #433 out of 812 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Alcon has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alcon's Days Sales Outstanding compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Alcon ranks #433 out of 812 companies for Days Sales Outstanding. This places Alcon in the lower half of its industry. The industry median Days Sales Outstanding is 65.17. Alcon's value of 66.80 is 2.5% above this benchmark. Historically, Alcon's own Days Sales Outstanding has ranged from 66.23 to 83.87 over the past decade. While the company's 10-year median is 72.04 vs. the industry median of 65.17, Alcon has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 65.17, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alcon's current Days Sales Outstanding of 66.80 is 2.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Alcon and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 65.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alcon's current Days Sales Outstanding is 66.80, which is near median its own 10-year median of 72.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alcon stock overvalued right now?
Based on GuruFocus' analysis, Alcon (XSWX:ALC) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF74.50, compared to a current price of CHF57.34 — trading 23% below its estimated fair value. The current Days Sales Outstanding is 66.80, which is near median its 10-year median of 72.04 and 2.5% above the Medical Devices & Instruments industry median of 65.17. Alcon's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Alcon (XSWX:ALC), the current Days Sales Outstanding is 66.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alcon (XSWX:ALC) Overvalued in 2026?
Based on GuruFocus' analysis, Alcon stock appears to be undervalued.
The current stock price of CHF57.34 is trading 23% below its estimated GF Value™ of CHF74.50.
GuruFocus considers Alcon to be Modestly Undervalued.
Key valuation signals for XSWX:ALC:
Days Sales Outstanding: 66.80 (near median its 10-year median of 72.04)
GF Value™: CHF74.50 vs. price of CHF57.34 (23% below fair value)
Industry Position: 2.5% above the Medical Devices & Instruments median (#433 of 812)
No single metric tells the full story. See the XSWX:ALC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
74GF Score
Get the complete analysis for XSWX:ALC
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ALC has been successfully added to your 
